These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 9393627)

  • 1. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
    Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
    Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
    Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
    Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies.
    De Gast GC; Van Houten AA; Haagen IA; Klein S; De Weger RA; Van Dijk A; Phillips J; Clark M; Bast BJ
    J Hematother; 1995 Oct; 4(5):433-7. PubMed ID: 8581381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
    Csóka M; Strauss G; Debatin KM; Moldenhauer G
    Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
    Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
    Haagen IA; van de Griend R; Clark M; Geerars A; Bast B; de Gast B
    Clin Exp Immunol; 1992 Dec; 90(3):368-75. PubMed ID: 1281055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.
    de Gast GC; Haagen IA; van Houten AA; Klein SC; Duits AJ; de Weger RA; Vroom TM; Clark MR; Phillips J; van Dijk AJ
    Cancer Immunol Immunother; 1995 Jun; 40(6):390-6. PubMed ID: 7543021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
    Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
    Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
    Haagen IA; Geerars AJ; de Lau WB; Clark MR; van de Griend RJ; Bast BJ; de Gast BC
    Blood; 1994 Jul; 84(2):556-63. PubMed ID: 7517719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.
    Haagen IA; de Lau WB; Bast BJ; Geerars AJ; Clark MR; de Gast BC
    Cancer Immunol Immunother; 1994 Dec; 39(6):391-6. PubMed ID: 7528094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
    Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
    Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
    Schlereth B; Quadt C; Dreier T; Kufer P; Lorenczewski G; Prang N; Brandl C; Lippold S; Cobb K; Brasky K; Leo E; Bargou R; Murthy K; Baeuerle PA
    Cancer Immunol Immunother; 2006 May; 55(5):503-14. PubMed ID: 16032400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
    Haagen IA
    Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells.
    Kaneko T; Fusauchi Y; Kakui Y; Masuda M; Akahoshi M; Teramura M; Motoji T; Okumura K; Mizoguchi H; Oshimi K
    Blood; 1993 Mar; 81(5):1333-41. PubMed ID: 8095165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
    Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
    Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow.
    Manzke O; Berthold F; Huebel K; Tesch H; Diehl V; Bohlen H
    Int J Cancer; 1999 Mar; 80(5):715-22. PubMed ID: 10048973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
    Fan D; Li W; Yang Y; Zhang X; Zhang Q; Yan Y; Yang M; Wang J; Xiong D
    J Hematol Oncol; 2015 Oct; 8():108. PubMed ID: 26444983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Production, identification and redirected cytotoxicity of CD3/CD19 bispecific monoclonal antibody].
    Chen X; Shen D; Sun T; Bai J; Huang L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Oct; 20(5):351-6. PubMed ID: 11717991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
    Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
    Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.